Chemotherapy-induced neuropathy: A comprehensive survey

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815

Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer

André, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Zaninelli, M., Clingan, P., Bridgewater, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032709 · Cited by 3,689

Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma

Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A., Facon, T., Harousseau, J.-L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043445 · Cited by 2,491

Paclitaxel (Taxol)

Rowinsky, E. K., & Donehower, R. C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321507 · Cited by 1,924

Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study

Cortes, J., O'Shaughnessy, J., Loesch, D., Blum, J. L., Vahdat, L. T., Petrakova, K., Chollet, P., Manikas, A., Diéras, V., Delozier, T., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60070-6 · Cited by 1,094

Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced Painful Peripheral Neuropathy: A Randomized Clinical Trial

Smith, E. M. L., Pang, H., Cirrincione, C., Fleishman, S., Paskett, E. D., Ahles, T., Bressler, L. R., Fadul, C. E., Knox, C., Le-Lindqwister, N., et al. (2013) · JAMA · doi:10.1001/jama.2013.2813 · Cited by 1,014

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

Moreau, P., Pylypenko, H., Grosicki, S., Karamanesht, I., Leleu, X., Grishunina, M., Rekhtman, G., Masliak, Z., Robak, T., Shubina, A., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70081-x · Cited by 920

OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer—A GERCOR Study

Tournigand, C., Cervantes, A., Figer, A., Lledo, G., Flesch, M., Buyse, M., Mineur, L., Carola, E., Etienne, P.-L., Rivera, F., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.0106 · Cited by 805

Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With Bortezomib

Richardson, P. G., Briemberg, H., Jagannath, S., Wen, P. Y., Barlogie, B., Berenson, J., Singhal, S., Siegel, D. S., Irwin, D., Schuster, M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.7779 · Cited by 649

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840

Seidman, A. D., Berry, D., Cirrincione, C., Harris, L., Muss, H., Marcom, P. K., Gipson, G., Burstein, H., Lake, D., Shapiro, C. L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6699 · Cited by 594

Platinum neurotoxicity pharmacogenetics

McWhinney, S. R., Goldberg, R. M., & McLeod, H. L. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0840 · Cited by 574

Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: Evidence for mitochondrial dysfunction

Flatters, S. J. L., & Bennett, G. J. (2006) · Pain · doi:10.1016/j.pain.2006.01.037 · Cited by 535

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial

Richardson, P. G., Sonneveld, P., Schuster, M., Irwin, D., Stadtmauer, E., Facon, T., Harousseau, J.-L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., et al. (2007) · Blood · doi:10.1182/blood-2006-08-036947 · Cited by 513

Peripheral Neuropathy Induced by Microtubule-Stabilizing Agents

Lee, J. J., & Swain, S. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.0543 · Cited by 472

Neurotoxicity of Commonly Used Antineoplastic Agents

Weiss, H. D., Walker, M. D., & Wiernik, P. H. (1974) · New England Journal of Medicine · doi:10.1056/nejm197407112910205 · Cited by 411

Efficacy and Safety of Ixabepilone (BMS-247550) in a Phase II Study of Patients With Advanced Breast Cancer Resistant to an Anthracycline, a Taxane, and Capecitabine

Perez, E. A., Lerzo, G., Pivot, X., Thomas, E., Vahdat, L., Bosserman, L., Viens, P., Cai, C., Mullaney, B., Peck, R., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.3849 · Cited by 393

Peripheral sensory neuropathy and cisplatin chemotherapy

Roelofs, R. I., Hrushesky, W., Rogin, J., & Rosenberg, L. (1984) · Neurology · doi:10.1212/wnl.34.7.934 · Cited by 370

Peripheral neuropathy from taxol and cisplatin combination chemotherapy: Clinical and electrophysiological studies

Chaudhry, V., Rowinsky, E. K., Sartorius, S. E., Donehower, R. C., & Cornblath, D. R. (1994) · Annals of Neurology · doi:10.1002/ana.410350310 · Cited by 363

Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity.

Gregg, R. W., Molepo, J. M., Monpetit, V. J., Mikael, N. Z., Redmond, D., Gadia, M., & Stewart, D. J. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.5.795 · Cited by 358

Prevention of Oxaliplatin-Related Neurotoxicity by Calcium and Magnesium Infusions

Gamelin, L., Boisdron‐Celle, M., Delva, R., Guerin‐Meyer, V., Ifrah, N., Morel, A., & Gamelin, E. C. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0666 · Cited by 346

A review on oxaliplatin-induced peripheral nerve damage

Argyriou, A. A., Polychronopoulos, P., Iconomou, G., Chroni, E., & Kalofonos, H. P. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.01.003 · Cited by 330

Peripheral Neuropathy Induced by Paclitaxel: Recent Insights and Future Perspectives

Scripture, C., Figg, W., & Sparreboom, A. (2006) · Current Neuropharmacology · doi:10.2174/157015906776359568 · Cited by 320

Phase II Study of Nelarabine (compound 506U78) in Children and Young Adults With Refractory T-Cell Malignancies: A Report From the Children’s Oncology Group

Berg, S. L., Blaney, S. M., Devidas, M., Lampkin, T. A., Murgo, A., Bernstein, M., Billett, A., Kurtzberg, J., Reaman, G., Gaynon, P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.426 · Cited by 318

Interventions for preventing neuropathy caused by cisplatin and related compounds

Albers, J. W., Chaudhry, V., Cavaletti, G., & Donehower, R. C. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005228.pub4 · Cited by 298

The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings

Cavaletti, G., Cornblath, D. R., Merkies, I. S. J., Postma, T. J., Rossi, E., Frigeni, B., Alberti, P., Bruna, J., Velasco, R., Argyriou, A. A., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mds329 · Cited by 293

Single-Agent Bortezomib in Previously Untreated Multiple Myeloma: Efficacy, Characterization of Peripheral Neuropathy, and Molecular Correlations With Response and Neuropathy

Richardson, P. G., Xie, W., Mitsiades, C., Chanan-Khan, A. A., Lonial, S., Hassoun, H., Avigan, D. E., Oaklander, A. L., Kuter, D. J., Wen, P. Y., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.3087 · Cited by 274

Paclitaxel-induced neuropathy

Postma, T. J., Vermorken, J. B., Liefting, A. J. M., Pinedo, H. M., & Heimans, J. J. (1995) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a059220 · Cited by 271

Neurotoxicity of Commonly Used Antineoplastic Agents

Weiss, H. D., Walker, M. D., & Wiernik, P. H. (1974) · New England Journal of Medicine · doi:10.1056/nejm197407182910305 · Cited by 268

Bortezomib-induced peripheral neurotoxicity: A neurophysiological and pathological study in the rat

Cavaletti, G., Gilardini, A., Canta, A., Rigamonti, L., Rodriguez-Menendez, V., Ceresa, C., Marmiroli, P., Bossi, M., Oggioni, N., D'Incalci, M., et al. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2006.11.010 · Cited by 265

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

Adams, R. A., Meade, A. M., Seymour, M. T., Wilson, R. H., Madi, A., Fisher, D., Kenny, S. L., Kay, E., Hodgkinson, E., Pope, M., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70102-4 · Cited by 264

Keloids: Pathophysiology and management

Robles, D. T., Moore, E., Draznin, M., & Berg, D. (2007) · Dermatology Online Journal · doi:10.5070/d32m43548r · Cited by 249

Vincristine Neurotoxicity: Pathophysiology and Management

Legha, S. S. (1986) · Medical Toxicology · doi:10.1007/bf03259853 · Cited by 243

A systematic review of phase‐II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma

Glasmacher, A., Hahn, C., Hoffmann, F., Naumann, R., Goldschmidt, H., von Lilienfeld‐Toal, M., Orlopp, K., Schmidt‐Wolf, I., & Gorschlüter, M. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05914.x · Cited by 237

Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy

Park, S. B., Lin, C. S.-Y., Krishnan, A. V., Goldstein, D., Friedlander, M. L., & Kiernan, M. C. (2009) · Brain · doi:10.1093/brain/awp219 · Cited by 231

Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy

Hammack, J. E., Michalak, J. C., Loprinzi, C. L., Sloan, J. A., Novotny, P. J., Soori, G. S., Tirona, M. T., Rowland, K. M., Stella, P. J., & Johnson, J. A. (2002) · Pain · doi:10.1016/s0304-3959(02)00047-7 · Cited by 231

Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, As First-Line Therapy in Patients With Metastatic Breast Cancer Previously Treated With Anthracycline Chemotherapy

Roché, H., Yelle, L., Cognetti, F., Mauriac, L., Bunnell, C., Sparano, J., Kerbrat, P., Delord, J.-P., Vahdat, L., Peck, R., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.7535 · Cited by 224

Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues

Delforge, M., Bladé, J., Dimopoulos, M. A., Facon, T., Kropff, M., Ludwig, H., Palumbo, A., Van Damme, P., San-Miguel, J. F., & Sonneveld, P. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70068-1 · Cited by 222

Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial

Broyl, A., Corthals, S. L., Jongen, J. L., van der Holt, B., Kuiper, R., de Knegt, Y., van Duin, M., el Jarari, L., Bertsch, U., Lokhorst, H. M., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70206-0 · Cited by 219

Neurotoxicity of bortezomib therapy in multiple myeloma: A single‐center experience and review of the literature

Badros, A., Goloubeva, O., Dalal, J. S., Can, I., Thompson, J., Rapoport, A. P., Heyman, M., Akpek, G., & Fenton, R. G. (2007) · Cancer · doi:10.1002/cncr.22921 · Cited by 217

Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial

Durand, J. P., Deplanque, G., Montheil, V., Gornet, J. M., Scotte, F., Mir, O., Cessot, A., Coriat, R., Raymond, E., Mitry, E., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr045 · Cited by 217

Randomized Double-Blind Placebo-Controlled Trial of Acetyl-L-Carnitine for the Prevention of Taxane-Induced Neuropathy in Women Undergoing Adjuvant Breast Cancer Therapy

Hershman, D. L., Unger, J. M., Crew, K. D., Minasian, L. M., Awad, D., Moinpour, C. M., Hansen, L., Lew, D. L., Greenlee, H., Fehrenbacher, L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.8738 · Cited by 214

Interaction of Vinca Alkaloids with Tubulin: A Comparison of Vinblastine, Vincristine, and Vinorelbine

Lobert, S., Vulevic, B., & Correia, J. J. (1996) · Biochemistry · doi:10.1021/bi953037i · Cited by 212

Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721

Mollman, J. E., Glover, D. J., Hogan, W. M., & FURMAN, R. E. (1988) · Cancer · Cited by 212

Glutathione S-Transferase P1 Polymorphism (Ile105Val) Predicts Cumulative Neuropathy in Patients Receiving Oxaliplatin-Based Chemotherapy

Lecomte, T., Landi, B., Beaune, P., Laurent-Puig, P., & Loriot, M.-A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2076 · Cited by 211

Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel

Xiao, W. H., Zheng, H., & Bennett, G. J. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2011.12.023 · Cited by 209

Mitochondrial-Mediated Disregulation of Ca2+ Is a Critical Determinant of Velcade (PS-341/Bortezomib) Cytotoxicity in Myeloma Cell Lines

Landowski, T. H., Megli, C. J., Nullmeyer, K. D., Lynch, R. M., & Dorr, R. T. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3684 · Cited by 202

Management of thalidomide toxicity.

Ghobrial, I. M., & Rajkumar, S. V. (2003) · PubMed · Cited by 201

Intravenous Calcium and Magnesium for Oxaliplatin-Induced Sensory Neurotoxicity in Adjuvant Colon Cancer: NCCTG N04C7

Grothey, A., Nikcevich, D. A., Sloan, J. A., Kugler, J. W., Silberstein, P. T., Dentchev, T., Wender, D. B., Novotny, P. J., Chitaley, U., Alberts, S. R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.5911 · Cited by 198

Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening

Verstappen, C. C. P., Koeppen, S., Heimans, J. J., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000154642.45474.28 · Cited by 196

Efficacy of lamotrigine in the management of chemotherapy‐induced peripheral neuropathy: A phase 3 randomized, double‐blind, placebo‐controlled trial, N01C3

Rao, R. D., Flynn, P. J., Sloan, J. A., Wong, G. Y., Novotny, P., Johnson, D. B., Gross, H. M., Renno, S. I., Nashawaty, M., & Loprinzi, C. L. (2008) · Cancer · doi:10.1002/cncr.23482 · Cited by 193

The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial

Kottschade, L. A., Sloan, J. A., Mazurczak, M. A., Johnson, D. B., Murphy, B. P., Rowland, K. M., Smith, D. A., Berg, A. R., Stella, P. J., & Loprinzi, C. L. (2011) · Supportive Care in Cancer · doi:10.1007/s00520-010-1018-3 · Cited by 173

Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats

Cavaletti, G., Tredici, G., Marmiroli, P., Petruccioli, M. G., Barajon, I., & Fabbrica, D. (1992) · Acta Neuropathologica · doi:10.1007/bf00227662 · Cited by 164

Long term effects of vincristine on the peripheral nervous system

Postma, T. J., Benard, B. A., Huijgens, P. C., Ossenkoppele, G. J., & Heimans, J. J. (1993) · Journal of Neuro-Oncology · doi:10.1007/bf01050259 · Cited by 154

Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-l-carnitine

Bianchi, G., Vitali, G., Caraceni, A. T., Ravaglia, S., Capri, G., Cundari, S., Zanna, C., & Gianni, L. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.04.028 · Cited by 152

Randomized Trial of 3-Hour Versus 24-Hour Infusion of High-Dose Paclitaxel in Patients With Metastatic or Locally Advanced Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26

Smith, R. E., Brown, A. M., Mamounas, E. P., Anderson, S., Lembersky, B. C., Atkins, J. H., Shibata, H. R., Báez, L., DeFusco, P. A., Davila, E., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3403 · Cited by 151

Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies

Cavaletti, G., & Jakubowiak, A. J. (2010) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2010.483303 · Cited by 149

Reduction of paclitaxel-induced peripheral neuropathy with glutamine.

Vahdat, L. T., Papadopoulos, K. P., Lange, D., Leuin, S. C., Kaufman, E. A., Donovan, D., Frederick, D., Bagiella, E., Tiersten, A., NICHOLS, G. L., et al. (2001) · PubMed · Cited by 149

Management of oxaliplatin-induced peripheral neuropathy.

Saif, M. W., & Reardon, J. (2005) · PubMed Central · Cited by 148

Motor neuropathy due to docetaxel and paclitaxel

Freilich, R. J., Balmaceda, C. M., Seidman, A. D., Rubin, M., & DeAngelis, L. M. (1996) · Neurology · doi:10.1212/wnl.47.1.115 · Cited by 144

Preventing Paclitaxel-Induced Peripheral Neuropathy: A Phase II Trial of Vitamin E Supplementation

Argyriou, A. A., Chroni, E., Koutras, A. K., Iconomou, G., Papapetropoulos, S., Polychronopoulos, P., & Kalofonos, H. P. (2006) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2006.03.013 · Cited by 134

Neurological adverse effects caused by cytotoxic and targeted therapies

Schiff, D., Wen, P. Y., & van den Bent, M. J. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.128 · Cited by 129

Neuropathy in multiple myeloma treated with thalidomide

Plasmati, R., Pastorelli, F., Cavo, M., Petracci, E., Zamagni, E., Tosi, P., Cangini, D., Tacchetti, P., Salvi, F., Bartolomei, I., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000267271.18475.fe · Cited by 126

Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics

Cavaletti, G., Alberti, P., & Marmiroli, P. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70131-0 · Cited by 123

Chemotherapy-induced neurotoxicity: the value of neuroprotective strategies.

Beijers, A. J. M., Jongen, J. L. M., & Vreugdenhil, G. (2012) · PubMed · Cited by 120

Chemotherapy-induced peripheral neuropathies: from clinical relevance to preclinical evidence

Balayssac, D., Ferrier, J., Descoeur, J., Ling, B., Pezet, D., Eschalier, A., & Authier, N. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2011.543417 · Cited by 119

Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis

Mauri, D. N., Kamposioras, K. V., Tsali, L., Bristianou, M., Valachis, A., Karathanasi, I., Georgiou, C., & Polyzos, N. P. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.10.006 · Cited by 116

Intermittent oxaliplatin (oxali) administration and time-to-treatment-failure (TTF) in metastatic colorectal cancer (mCRC): Final results of the phase III CONcePT trial

Grothey, A., Hart, L. L., Rowland, K. M., Ansari, R., Alberts, S. R., Chowhan, N. M., Shpilsky, A., & Hochster, H. S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.4010 · Cited by 114

The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis

Terpos, E., Kastritis, E., Ρούσσου, Μ., Heath, D., Christoulas, D., Anagnostopoulos, N. I., Eleftherakis-Papaiakovou, E., Tsionos, K., Croucher, P. I., & Dimopoulos, M. A. (2008) · Leukemia · doi:10.1038/leu.2008.235 · Cited by 114

Taxol impairs anterograde axonal transport of microinjected horseradish peroxidase in dorsal root ganglia neurons in vitro

Theiß, C., & Meller, K. (2000) · Cell and Tissue Research · doi:10.1007/s004410050019 · Cited by 110

Taxol impairs anterograde axonal transport of microinjected horseradish peroxidase in dorsal root ganglia neurons in vitro

Theiß, C., & Meller, K. (1999) · Cell and Tissue Research · doi:10.1007/s004419900120 · Cited by 107

Genetic Factors Underlying the Risk of Thalidomide-Related Neuropathy in Patients With Multiple Myeloma

Johnson, D. C., Corthals, S. L., Walker, B. A., Ross, F. M., Gregory, W. M., Dickens, N. J., Lokhorst, H. M., Goldschmidt, H., Davies, F. E., Durie, B. G. M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.0792 · Cited by 104

FDA Drug Approval Summary: Nelarabine (Arranon®) for the Treatment of T-Cell Lymphoblastic Leukemia/Lymphoma

Cohen, M. H., Johnson, J. R., Justice, R. L., et al. (2008) · The Oncologist · doi:10.1634/theoncologist.2006-0017 · Cited by 99

Immune-mediated neuropathies in myeloma patients treated with bortezomib

Ravaglia, S., Corso, A., Piccolo, G., Lozza, A., Alfonsi, E., Mangiacavalli, S., Varettoni, M., Zappasodi, P., Moglia, A., Lazzarino, M., et al. (2008) · Clinical Neurophysiology · doi:10.1016/j.clinph.2008.08.007 · Cited by 98

Clinical and electrophysiological studies in vincristine induced neuropathy.

Pal, P. K. (1999) · PubMed · Cited by 96

Persistent neuropathy after treatment with cisplatin and oxaliplatin

Brouwers, E. E. M., Huitema, A. D. R., Boogerd, W. J., Beijnen, J. H., & Schellens, J. H. M. (2009) · Acta Oncologica · doi:10.1080/02841860902806609 · Cited by 94

Thalidomide in patients with malignant pleural mesothelioma

Baas, P., Boogerd, W. J., Dalesio, O., Haringhuizen, A., Custers, F. L. J., & van Zandwijk, N. (2004) · Lung Cancer · doi:10.1016/j.lungcan.2004.10.005 · Cited by 92

Interventions for preventing neuropathy caused by cisplatin and related compounds

Albers, J. W., Chaudhry, V., Cavaletti, G., et al. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005228.pub3 · Cited by 86

Efficacy of the neuropeptide ORG.2766 in the prevention and treatment of cisplatin-induced neurotoxicity in rats

van der Hoop, R. G., Koning, P. D., Boven, E., et al. (1988) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(88)90293-3 · Cited by 79

Neurophysiological Study of Peripheral Neuropathy after High-Dose Paclitaxel

Openshaw, H., Beamon, K., Synold, T. W., Longmate, J., Slatkin, N. E., Doroshow, J. H., Forman, S. J., Margolin, K. A., Morgan, R. J., Shibata, S., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0772-03 · Cited by 78

Paclitaxel (Taxol) induces cumulative mild neurotoxicity

van Gerven, J., Moll, J. W. B., van den Bent, M. J., Bontenbal, M., van der Burg, M. E. L., Verweij, J., & Vecht, C. J. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90459-6 · Cited by 77

Oxaliplatin-Induced Neuropathy in Colorectal Cancer

Weickhardt, A. J., Wells, K. R., & Messersmith, W. A. (2011) · Journal of Oncology · doi:10.1155/2011/201593 · Cited by 74

Glutamate ameliorates experimental vincristine neuropathy.

Boyle, F. M., Wheeler, H., & Shenfield, G. M. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20981-8 · Cited by 69

Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221)

Sucheston, L. E., Zhao, H., Yao, S., Zirpoli, G., Liu, S., Barlow, W. E., Moore, H. C. F., Budd, G. T., Hershman, D. L., Davis, W., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1671-3 · Cited by 68

Cisplatin induced neuropathy: Central, peripheral and autonomic nerve involvement

Boogerd, W. J., Huinink, W. W. T. B., Dalesio, O., Hoppenbrouwers, W. J. J. F., & van der Sande, J. J. (1990) · Journal of Neuro-Oncology · doi:10.1007/bf02341156 · Cited by 68

Pathophysiology and Animal Models of Cancer-Related Painful Peripheral Neuropathy

Bennett, G. J. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-s503 · Cited by 61

Taxane-induced peripheral neuropathy has good long-term prognosis: a 1- to 13-year evaluation

Osmani, K., Vignes, S., Aissi, M., Wade, F. M., Milani, P., Levy, B. I., & Kubis, N. (2012) · Journal of Neurology · doi:10.1007/s00415-012-6442-5 · Cited by 59

Microtubules, Axonal Transport, and Neuropathy

Holzbaur, E. L. F., & Scherer, S. S. (2011) · New England Journal of Medicine · doi:10.1056/nejmcibr1112481 · Cited by 56

Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: Phase I clinical trial of three dosing schedules in patients with solid malignancies

Sharma, R. A., Steward, W. P., Daines, C. A., Knight, R., O'Byrne, K. J., & Dalgleish, A. G. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.05.018 · Cited by 52

Vincristine exacerbates asymptomatic Charcot–Marie–Tooth disease with a novel EGR2 mutation

Nakamura, T., Hashiguchi, A., Suzuki, S., Uozumi, K., Tokunaga, S., & Takashima, H. (2012) · Neurogenetics · doi:10.1007/s10048-012-0313-1 · Cited by 49

Peripheral neuropathy associated with weekly oral 5-fluorouracil, leucovorin and eniluracil

Saif, M. W., Wilson, R. H., Harold, N., Keith, B. D., Dougherty, D. S., & Grem, J. L. (2001) · Anti-Cancer Drugs · doi:10.1097/00001813-200107000-00006 · Cited by 34

Neurological complications of chemotherapy

Cherubini, G. B., & Platt, S. R. (2008) · Companion animal · doi:10.1111/j.2044-3862.2008.tb00291.x · Cited by 18

Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis

Seretny, M., Currie, G. L., Sena, E. S., Ramnarine, S., Grant, R., MacLeod, M. R., Colvin, L. A., & Fallon, M. (2014) · Pain · doi:10.1016/j.pain.2014.09.020 · Cited by 1,555

Lipid Nanoparticle Delivery of Chemically Modified NGF R100W mRNA Alleviates Peripheral Neuropathy

Yu, X., Yang, Z., Zhang, Y., Xia, J., Zhang, J., Han, Q., Yu, H., Wu, C., Xu, Y., Xu, W., et al. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202202127 · Cited by 38